This infographic highlights the role of APRIL in a pre-hit 1 step that drives the 4-hit cascade.1 References 1. Mathur M, et al. J Clin Med. 2023;12(21):6927. Read More
Join us for this webinar to learn more about mental health in IgAN and how it impacts patients, caregivers, healthcare providers, as well as related stressors. Read More
The goal of this podcast is to discuss the evidence that supports proteinuria reduction as a surrogate marker in IgA Nephropathy clinical trials. Read More
Welcome to NephU’s Hot Topics in Nephrology Series featuring various experts in the field of nephrology. In this podcast series, thought leaders will share their expertise and perspectives on the… Read More
The goal of this on-demand webinar is to provide a detailed overview of the Four-Hit hypothesis as well as explain the role of APRIL in disease pathogenesis. Read More
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. Read More
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.